Table 1 Case 1’s creatine kinase level against time and changes in antipsychotic type
From: Aripiprazole-induced quasi-neuroleptic malignant syndrome: two case reports
Time period | Creatine kinase level (U/L) (reference range 46–171 U/L) | Antipsychotic medication |
|---|---|---|
Day 1 (day of admission) | ||
Day 2 | Started on aripiprazole 10 mg twice daily | |
Day 5 | Aripiprazole increased to 10 mg thrice daily | |
Day 16 | First dose of aripiprazole 400 mg depot given | |
Day 19 | 1311 | |
Day 21 | 10,413 | |
Day 22 | 16,729 | |
Day 25 | 3652 | |
Day 30 | 2511 | |
Day 33 | 1101 | |
Day 44 | 283 | |
Day 47 | Second dose of aripiprazole 400 mg depot given | |
Day 50 | 1288 | |
Day 51 | Aripiprazole depot discontinued | |
Day 52 | 3870 | |
Day 62 | 213 | |
Day 68 | Started on risperidone 2 mg every night | |
Day 71 | 134 | risperidone increased to 4 mg every night |
Day 86 | 210 | |
Day 96 | Started on paliperidone depot | |
Day 112 | 124 |